MIIP and neoplasm: In addition, our recent studies have demonstrated that MIIP is downregulated in prostate cancer, and its overexpression inhibits tumor growth and epithelial-mesenchymal transition by modulating PP1α-AKT signaling and the miR-181a/b-5p-KLF17 axis, respectively23,24.